Vanguard Group
CRDF icon

Vanguard Group’s Cardiff Oncology CRDF Stock Holding History

Vanguard Group’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$10.5M Buy
3,722,085
+133,152
+4% +$309K ﹤0.01% 2943
2025
Q3 		$7.39M Sell
3,588,933
-139,401
-4% -$385K ﹤0.01% 3133
2025
Q2 		$11.7M Buy
3,728,334
+612,965
+20% +$1.87M ﹤0.01% 2812
2025
Q1 		$9.78M Buy
3,115,369
+830,452
+36% +$3.28M ﹤0.01% 2855
2024
Q4 		$9.92M Buy
2,284,917
+113,473
+5% +$355K ﹤0.01% 2966
2024
Q3 		$5.8M Buy
2,171,444
+35,106
+2% +$82.9K ﹤0.01% 3214
2024
Q2 		$4.74M Buy
2,136,338
+215,081
+11% +$811K ﹤0.01% 3280
2024
Q1 		$10.3M Buy
1,921,257
+9,468
+0.5% +$25.2K ﹤0.01% 2952
2023
Q4 		$2.83M Sell
1,911,789
-31,129
-2% -$37.7K ﹤0.01% 3475
2023
Q3 		$2.7M Hold
1,942,918
– – ﹤0.01% 3488
2023
Q2 		$2.86M Hold
1,942,918
– – ﹤0.01% 3541
2023
Q1 		$3.21M Hold
1,942,918
– – ﹤0.01% 3501
2022
Q4 		$2.72M Buy
1,942,918
+870
+0% +$1.25K ﹤0.01% 3552
2022
Q3 		$2.99M Buy
1,942,048
+186,392
+11% +$449K ﹤0.01% 3586
2022
Q2 		$3.86M Sell
1,755,656
-157,757
-8% -$264K ﹤0.01% 3514
2022
Q1 		$4.75M Sell
1,913,413
-45,522
-2% -$161K ﹤0.01% 3554
2021
Q4 		$11.8M Buy
1,958,935
+145,987
+8% +$870K ﹤0.01% 3128
2021
Q3 		$12.1M Buy
1,812,948
+166,904
+10% +$1.05M ﹤0.01% 3136
2021
Q2 		$10.9M Buy
1,646,044
+72,134
+5% +$612K ﹤0.01% 3153
2021
Q1 		$14.6M Buy
1,573,910
+27,533
+2% +$334K ﹤0.01% 2949
2020
Q4 		$27.8M Buy
1,546,377
+514,975
+50% +$9.05M ﹤0.01% 2481
2020
Q3 		$14.6M Buy
1,031,402
+737,026
+250% +$4.87M ﹤0.01% 2600
2020
Q2 		$1.48M Buy
294,376
+23,593
+9% +$48.3K ﹤0.01% 3521
2020
Q1 		$273K Sell
270,783
-3,136
-1% -$4.43K ﹤0.01% 3811
2019
Q4 		$340K Hold
273,919
– – ﹤0.01% 3865
2019
Q3 		$414K Sell
273,919
-11,231
-4% -$21.9K ﹤0.01% 3856
2019
Q2 		$713K Buy
285,150
+217,386
+321% +$697K ﹤0.01% 3760
2019
Q1 		$254K Buy
67,764
+9,414
+16% +$33.7K ﹤0.01% 3879
2018
Q4 		$184K Buy
58,350
+18,512
+46% +$84.4K ﹤0.01% 3914
2018
Q3 		$195K Buy
39,838
+33,294
+509% +$158K ﹤0.01% 4007
2018
Q2 		$30K Sell
6,544
-7,138
-52% -$119K ﹤0.01% 4115
2018
Q1 		$344K Buy
13,682
+2,923
+27% +$72.1K ﹤0.01% 3864
2017
Q4 		$238K Sell
10,759
-1,039
-9% -$46K ﹤0.01% 3900
2017
Q3 		$620K Buy
11,798
+5,125
+77% +$320K ﹤0.01% 3702
2017
Q2 		$606K Sell
6,673
-4,062
-38% -$262K ﹤0.01% 3690
2017
Q1 		$889K Buy
10,735
+29
+0.3% +$3.94K ﹤0.01% 3614
2016
Q4 		$1.62M Sell
10,706
-3,018
-22% -$705K ﹤0.01% 3428
2016
Q3 		$4.44M Buy
13,724
+127
+0.9% +$46.3K ﹤0.01% 3065
2016
Q2 		$4.43M Buy
13,597
+421
+3% +$145K ﹤0.01% 3045
2016
Q1 		$4.41M Buy
13,176
+210
+2% +$71.4K ﹤0.01% 3031
2015
Q4 		$5.04M Buy
12,966
+761
+6% +$298K ﹤0.01% 2983
2015
Q3 		$5M Buy
12,205
+3,042
+33% +$1.59M ﹤0.01% 2969
2015
Q2 		$6.7M Buy
9,163
+1,356
+17% +$962K ﹤0.01% 2872
2015
Q1 		$3.83M Buy
7,807
+2,510
+47% +$1.07M ﹤0.01% 3121
2014
Q4 		$1.64M Buy
5,297
+34
+0.6% +$11K ﹤0.01% 3352
2014
Q3 		$1.74M Buy
5,263
+190
+4% +$56.9K ﹤0.01% 3322
2014
Q2 		$1.28M Buy
5,073
+271
+6% +$86.8K ﹤0.01% 3420
2014
Q1 		$1.98M Buy
4,802
+536
+13% +$232K ﹤0.01% 3226
2013
Q4 		$1.76M Buy
4,266
+259
+6% +$115K ﹤0.01% 3237
2013
Q3 		$2.07M Buy
4,007
+1,842
+85% +$1.05M ﹤0.01% 3117
2013
Q2 		$1.09M Buy
+2,165
New +$978K ﹤0.01% 3286

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

Vanguard Group's CRDF Position: Q4 2025 in Review

Vanguard Group increased its Cardiff Oncology (CRDF) stake by 3.7% in Q4 2025, buying an estimated $309K and bringing the position to 3,722,085 shares worth $10.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2943.

Vanguard Group first reported a position in CRDF in Q2 2013 and has held it in 51 quarters since. The position peaked at $27.8M in Q4 2020. 110 funds tracked by Wall St. Rank hold CRDF as of Q4 2025.

  • Vanguard Group held 3,722,085 shares of Cardiff Oncology worth $10.5M as of Q4 2025.
  • Vanguard Group bought 133,152 Cardiff Oncology shares in Q4 2025, an estimated $309K.
  • Cardiff Oncology made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2943 holding.
  • Vanguard Group first reported a position in Cardiff Oncology in Q2 2013 and has held it in 51 quarters since.
  • Vanguard Group's Cardiff Oncology position peaked at $27.8M in Q4 2020.
  • 110 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.